ReviewCureus2025
Optimizing Cardiovascular Outcomes With Bisoprolol: An Evidence-Based Perspective.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sacubitril valsartan combined with bisoprolol reduces doxorubicin-induced cardiotoxicity in rats by attenuating oxidative stress.Experimental biology and medicine (Maywood, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cardiovascular continuum is the developmental process of cardiovascular diseases (CVDs) leading to heart failure (HF) and sudden cardiac death. Beta-blockers (BBs) are at the forefront of managing conditions along this continuum, ranging from cardiovascular (CV) risk factors to heart failure. In particular, bisoprolol proved to be a highly cardio-selective BB with a favourable pharmacokinetic profile, demonstrating long-term safety, good tolerability, and proven efficacy in reducing cardiac events, including arrhythmias and mortality in patients with heart failure with reduced ejection fraction (HFrEF). This evidence-based perspective showcased numerous clinical studies revealing the utility of bisoprolol in managing patients with CVDs, particularly HFrEF and stable angina. It also included safety evidence for bisoprolol in patients with renal and hepatic dysfunction, etc. Expert opinions from leading cardiologists across India further reinforce the role of bisoprolol as a first-line therapy in managing HFrEF and stable angina, making its usage suitable for HFrEF and angina patients with special emphasis on comorbidities, such as chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.